Monograph: valGANciclovir Hydrochloride

valGANciclovir Hydrochloride

Die Inhalte stehen nur registrierten Benutzern zur Verfügung.

Sie sind zum ersten mal hier und möchten die Datenbank 10-Tage kostenlos testen, dann registrieren Sie sich einmalig. Nach der Registrierung melden Sie sich mit Ihrem Benutzernamen und Passwort an.

Sie sind bereits bei DrugBase registriert und möchten diese Datenbank 10-Tage kostenlos und unverbindlich testen? Dann melden Sie sich mit Ihren Zugangsdaten an und wählen Sie anschließend die Datenbank, die Sie testen möchten.

Full Title

valGANciclovir Hydrochloride

Generic Name

valGANciclovir Hydrochloride

Chemical Name

...

INV Number

...

Synonym

...

Classification

CAS Number

...

Introduction

Introduction

...

...

Description

...

Spectrum

...

Resistance

...

...

Uses

Uses

...

Treatment of Cytomegalovirus Infection and Disease

...

Cytomegalovirus Retinitis

...

Clinical Experience

...

Extraocular Cytomegalovirus Infections

...

Congenital Cytomegalovirus Disease

...

Prevention of Cytomegalovirus Infection and Disease

...

Solid Organ Transplant Recipients

...

Clinical Experience

...

Hematopoietic Stem Cell Transplant Recipients

...

...

Dosage and Administration

Dosage and Administration

...

Administration

...

Oral Solution

...

Dosage

...

Adult Dosage

...

Cytomegalovirus Retinitis

...

Cytomegalovirus Esophagitis or Colitis

...

Prevention of Cytomegalovirus Infection and Disease in Transplant Recipients

...

Pediatric Dosage

...

Cytomegalovirus Retinitis

...

Congenital Cytomegalovirus Disease

...

Prevention of Cytomegalovirus Infection and Disease in Transplant Recipients

...

Special Populations

...

Renal Impairment

...

Cytomegalovirus Retinitis

...

Table 1. Dosage of Valganciclovir for Management of CMV Retinitis in Adults with Renal Impairment1

...

Geriatric Patients

...

...

Cautions

Cautions

...

Contraindications

...

Warnings/Precautions

...

Warnings

...

Hematologic Effects

...

Impairment of Fertility

...

Teratogenesis

...

Mutagenicity and Carcinogenicity

...

Other Warnings/Precautions

...

Renal Effects

...

Handling and Disposal

...

Specific Populations

...

Pregnancy

...

Lactation

...

Pediatric Use

...

Geriatric Use

...

Hepatic Impairment

...

Renal Impairment

...

Common Adverse Effects

...

...

Drug Interactions

Drug Interactions

...

Antibacterial Agents

...

Imipenem and Cilastatin Sodium

...

Trimethoprim

...

Other Antibacterials

...

Antifungal Agents

...

Amphotericin B

...

Flucytosine

...

Antineoplastic Agents

...

Antiretroviral Agents

...

Didanosine

...

Tenofovir

...

Zidovudine

...

Immunosuppressive Agents

...

Cyclosporine

...

Mycophenolate Mofetil

...

Tacrolimus

...

Probenecid

...

...

Pharmacokinetics

Pharmacokinetics

...

Absorption

...

Bioavailability

...

Food

...

Plasma Concentrations

...

Distribution

...

Extent

...

Plasma Protein Binding

...

Elimination

...

Metabolism

...

Elimination Route

...

Half-life

...

Special Populations

...

...

Advice to Patients

Advice to Patients

...

...

Preparations

Preparations

...

valGANciclovir Hydrochloride

...

...

Common general statement Elements

Additional Information

...

...

References

References

...

...

Copyright

AHFS® Drug Information. © Copyright, 1959-2019, Selected Revisions August 12, 2019. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814.

† Use is not currently included in the labeling approved by the US Food and Drug Administration.

Quelle

AHFS Drug Information